We previously reported 1 the presence of amyloid-β protein (Aβ) deposits in individuals with Creutzfeldt-Jakob disease (CJD) who had been treated during childhood with human cadaveric pituitaryderived growth hormone (c-hGH) contaminated with prions. The marked deposition of parenchymal and vascular Aβ in these relatively young individuals with treatment-induced (iatrogenic) CJD (iCJD), in contrast to other prion-disease patients and population controls, allied with the ability of Alzheimer's disease brain homogenates to seed Aβ deposition in laboratory animals, led us to argue that the implicated c-hGH batches might have been contaminated with Aβ seeds as well as with prions. However, this was necessarily an association, and not an experimental, study in humans and causality could not be concluded. Given the public health importance of our hypothesis, we proceeded to identify and biochemically analyse archived vials of c-hGH. Here we show that certain c-hGH batches to which patients with iCJD and Aβ pathology were exposed have substantial levels of Aβ 40 , Aβ 42 and tau proteins, and that this material can seed the formation of Aβ plaques and cerebral Aβ−amyloid angiopathy in intracerebrally inoculated mice expressing a mutant, humanized amyloid precursor protein. These results confirm the presence of Aβ seeds in archived c-hGH vials and are consistent with the hypothesized iatrogenic human transmission of Aβ pathology. This experimental confirmation has implications for both the prevention and the treatment of Alzheimer's disease, and should prompt a review of the risk of iatrogenic transmission of Aβ seeds by medical and surgical procedures long recognized to pose a risk of accidental prion transmission 2, 3 . Human prion diseases occur most commonly as sporadic or inherited conditions but, critically, are also experimentally transmissible, and rare cases are acquired by environmental exposure to infectious prions via diet or medical procedures 2 . This aetiological triad in prion disorders was thought to be unique amongst neurodegenerative diseases, but growing evidence from experimental cellular and animal models has implicated the propagation and spread of multimeric assemblies of misfolded host proteins in the pathogenesis of Alzheimer's, Parkinson's and other neurodegenerative conditions 2, 4 . Iatrogenic transmission of CJD, an invariably lethal neurodegenerative disease, can result following a range of medical and surgical procedures 2, 5 . The range of incubation periods of acquired prion diseases is known to span more than five decades 6 . Before 1985, when the risk of causing iCJD was not appreciated, children with short stature were treated with growth hormone extracted from large pools of cadaverderived pituitary glands, some of which would have been infected with prions 7 . More than 200 individuals treated with c-hGH worldwide have died of iCJD. We previously reported moderate to severe greymatter and vascular Aβ pathology in four of eight relatively young adults who had died of iCJD following childhood treatment with c-hGH 1 . A further two had focal Aβ pathology and only one was entirely negative for Aβ. All eight lacked genetic risk factors for Alzheimer's disease or cerebral Aβ−amyloid angiopathy (CAA). These findings stood in marked contrast to other prion disease and population controls and suggested that some of the c-hGH with which they were treated was contaminated with Aβ seeds as well as human prions. While these individuals did not have the full diagnostic neuropathological features of Alzheimer's disease-which also requires the presence of intracellular neurofibrillary tangles-some did have undoubted CAA disease with circumferential vessel-wall degeneration. Had they not died of iCJD at a relatively young age 1 , these individuals would have been expected to develop cerebral haemorrhage.
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CAA can occur independently of Alzheimer's disease, but at autopsy CAA is detected in the large majority of Alzheimer's cases 8, 9 . That CAA, a pathology that leads to cerebral haemorrhage and dementia, is most often caused by Aβ deposition in blood vessels is undoubted 10 . Indeed, as with Alzheimer's disease, autosomal dominant mutations in, or triplication of, the amyloid precursor protein (APP) gene can cause CAA [11] [12] [13] . The transmissibility of CAA, and potentially Alzheimer's disease, by iatrogenic routes raises important public health issues and would also 1 MRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, UK. 2 Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 3 Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako, Japan. 4 Division of Neuropathology, National
Hospital for Neurology and Neurosurgery, London, UK. *e-mail: jc@prion.ucl.ac.uk Letter reSeArCH indicate a clear shift in understanding their aetiology and suggest new approaches to prevention and treatment 2, 3 . Alternative interpretations of our findings have been proposed 14, 15 , although we have not considered these to be as plausible as the human transmission hypothesis 16, 17 . Given the potential public health importance of our findings, we proceeded to examine experimentally whether c-hGH batches to which these patients were exposed contained viable Aβ seeding activity, albeit after storage for more than 30 years.
In the UK, 1,883 patients were treated with c-hGH over the period 1958-1985 and 80 have so far developed iCJD (to July 2018), with recent incubation periods exceeding 40 years 7, 18 . During this period of treatment, multiple preparations using several different extraction methods were used, and patients generally received multiple batches from different preparations. However, one preparation, produced by the Hartree-modified Wilhelmi procedure (HWP), was received by all individuals who went on to develop iCJD 7, 18 . It is thought that sizeexclusion chromatography, used in non-Wilhelmi preparation methods, may have reduced prion contamination 7 . Fortuitously, Public Health England has maintained an archive of vials of c-hGH batches used to treat patients and we were able to obtain vials from a range of batches and production methods to which the eight patients we described 1 were exposed, plus additional vials from two further HWP batches (Table 1  and Extended Data Table 1) .
We analysed vial contents biochemically for the presence of Aβ peptides (x-40 and x-42) and tau protein (Table 1 and Methods). All HWP vials analysed were clearly positive for Aβ x-40 and tau, and all but one were also positive for Aβ x-42 peptides. Aβ and tau levels in vials from all other c-hGH purification methods examined-FL (Lowry preparation), LJ (Roos method) and TPL (Centre for Applied Microbiological Research) 19 -were below the limits of detection. There was therefore unequivocal biochemical evidence for the presence of Aβ peptides and tau protein in some of the batches (produced by the HWP method) to which iCJD patients with Aβ pathology were exposed. However, to determine whether seeding activity is present in this material requires a biological rather than a biochemical assay, as the composition and structure of seed-competent Aβ entities is unknown. Indeed, total Aβ peptide concentrations may be misleading in this regard.
For seeding studies, we used homozygous APP NL-F knock-in mice 20 , which express APP bearing the Swedish (KM670/671NL) and Beyreuther/Iberian (I716F) mutations, with a humanized Aβ domain; these mice produce the first signs of Aβ deposition at around six months of age 21 . We conducted extensive in-house time-course studies of uninoculated App NL-F/NL-F mice (C57BL/6J background) and confirmed a similar evolution of pathology to that described previously 21 . Inoculating these mice with brain homogenates (1% w/v) prepared from three autopsy-confirmed typical Alzheimer's patients (designated AD 1-3) or a normal control individual, or with vehicle alone (phosphate-buffered saline, PBS)-intracerebrally injected into groups of female App NL-F/NL-F mice at 6−8 weeks of age-showed clear seeding of Aβ pathology from the Alzheimer's cases (Extended Data Fig. 1 There were highly significant differences between vehicle (PBS)-inoculated mice and those inoculated with either AD brain homogenates or c-hGH preparations (PBS, n = 25; AD1, n = 15; PBS versus AD1, P < 0.0001; AD2, n = 15; PBS versus AD2, P < 0.0001; AD3, n = 14; PBS versus AD3, P < 0.0001; c-hGH HWP 42, n = 10; PBS versus HWP 42, P < 0.0001; c-hGH HWP 51, n = 8; PBS versus HWP 51, P < 0.0001; one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison test). There were no significant differences between PBS-inoculated mice and those inoculated with control human brain homogenate or rec-hGH (PBS, n = 25; control brain, n = 15, PBS versus control brain, P = 0.99; rec-hGH, n = 5, PBS versus rec-hGH, P = 0.99). Data are expressed as means ± standard deviation; n = number of mice per group. There was no significant difference between PBS-inoculated, control-braininoculated or rec-hGH-inoculated mice (PBS, n = 25; control brain, n = 15; PBS versus control brain, P = 0.99; rec-hGH, n = 5; PBS versus rec-hGH, P > 0.99). However, there were significant differences between PBS-inoculated and AD-or c-hGH-inoculated mice (PBS, n = 25; AD1, n = 15; PBS versus AD1, P = 0.007; AD2, n = 15; PBS versus AD2, P < 0.0001; AD3, n = 14; PBS versus AD3, P = 0.0002; c-hGH HWP 42, n = 10; PBS versus HWP 42, P < 0.0001; c-hGH HWP 51, n = 8; PBS versus HWP 51, P = 0.002; one-way ANOVA followed by Dunnett's multiple comparison test). Data are expressed as means ± standard deviation. NL-F/NL-F mice inoculated with PBS or normal brain had only occasional parenchymal plaques in the cerebral cortex and hippocampus, while the cerebellum, olfactory bulb and other areas entirely lacked plaques. However, at this time point widespread parenchymal plaques were evident in the cerebral cortex, hippocampus, corpus callosum, cerebellum and olfactory bulb in all AD-brain-inoculated animals (Fig. 3) . The mean percentage area covered by parenchymal plaques was significantly higher in AD-braininoculated mice than in PBS-inoculated mice (PBS control versus AD1, P = 0.017; AD2, P < 0.0001; AD3, P = 0.0005; data not shown). The difference in parenchymal Aβ deposition between AD-and controlinoculated mice was most pronounced in the cerebellum, where deposition was almost completely absent in PBS-or normal-braininoculated mice, but marked in AD-inoculated animals ( Fig. 2a) .
At 360 d.p.i., the localization of plaques observed in AD-braininoculated mice was similar but more severe than at 240 d.p.i. Notably, at this time point in PBS-and normal-brain-inoculated mice, CAA was evident only in some dorsal meningeal blood vessels over the cerebral cortex; in marked contrast, in AD-brain-inoculated mice Aβ deposition was seen in almost all meningeal blood vessels (n = 15 mice per group; Extended Data Fig. 1) .
To investigate the possible toxicity of intracerebrally administered human growth hormone in mice before we used the scarce c-hGH samples, we inoculated groups of three female C57BL/6J mice with 30 µl of recombinant human growth hormone (rec-hGH) at 1.2, 3.6 or 11 mg ml
, corresponding to doses of 0.1, 0.3 and 1 international units (IU) respectively. There was no evidence of toxicity in any of the mice, which were culled at 240 d.p.i. When mice (n = 2) were injected with a higher concentration of recombinant growth hormone (20 mg ml −1 ; 1.8 IU), they died immediately after the injection.
To establish whether seeding activity was present in Aβ-positive c-hGH batches, we used vials from c-hGH batches HWP 42 and 51-for which sufficient material was available for inoculation into groups of mice-for similar intracerebral injection into female congenic App NL-F/NL-F mice at 6−8 weeks of age. We expected these seeds, if present, to be at a very low titre by comparison with AD-brain homogenate and therefore used the much more efficient transmission route of intracerebral injection of c-hGH, rather than the peripheral injection that patients with iCJD underwent, in order to optimize the chance of detecting seeds in this scarce material 22 . We also inoculated rec-hGH as a further control, in case growth hormone itself might induce Aβ deposition. Mice received doses of 0.3 IU of HWP 42, 0.75 IU of HWP 51 or 1 IU of rec-hGH.
As additional experimental controls, AD-and normal-brain 1% w/v homogenate, vehicle alone, HWP 42 and HWP 51 were also injected into wild-type C57BL/6J mice at 6-8 weeks of age. All mice were analysed at 240 d.p.i. As expected, none of the wild-type C57BL/6J mice groups, expressing only murine APP, developed Aβ deposition (n = 8-10 mice per group; data not shown). Similarly, no cerebellar Aβ deposits were detected in rec-hGH-inoculated App NL-F/NL-F mice (n = 5 mice per group) and the CAA score was not statistically different from that of PBS-or normal-brain-inoculated groups (Figs. 1, 2b and 4) .
By contrast, CAA and cerebellar Aβ deposits were clearly evident in App NL-F/NL-F mice injected with HWP 42 or HWP 51 (Figs. 1, 2b, 4 and Extended Data Fig. 2 ), demonstrating the presence of seeding activity in archived HWP c-hGH vials. That the degree of CAA and cerebellar Aβ deposition in c-hGH-inoculated App NL-F/NL-F mice was less pronounced than in those inoculated with AD brain is consistent with the expected much higher seed titre in AD brain than in the archived c-hGH samples. Indeed, it is remarkable that detectable seeding activity has persisted at all after decades of storage.
Our proposal that human transmission of Aβ pathology had occurred as a result of intramuscular injection of c-hGH is now firmly supported by experimental evidence. While the individuals we described in our earlier report 1 did not meet the full neuropathological criteria for Alzheimer's disease, they might have done so if they had not died of iCJD at a relatively young age. Although tau pathology was not detected in the iCJD patients, it is interesting that the HWP c-hGH batches to which these individuals were exposed also contained biochemically measurable levels of tau. In future studies it will be important to determine whether the tau in c-hGH vials can seed Letter reSeArCH aggregation in mice expressing human tau. However, it is important to emphasize that the seeded Aβ deposition is not benign: several of these patients had an undoubted disease caused by Aβ deposition-CAA. This can now be described as iatrogenic CAA (iCAA) and CAA can be considered a transmissible disorder, with attendant public health implications.
After the publication of our original report suggesting human transmission of Aβ via c-hGH therapy 1 -which raised the possibility that it can also be transmitted by other routes known to be a risk for the transmission of CJD prions-there have been several published reports of Aβ deposition in young individuals following neurosurgical procedures (notably involving dura mater grafting), as well as following c-hGH inoculation [23] [24] [25] [26] [27] [28] . Although we reiterate that there is no suggestion that Alzheimer's disease is contagious, and no supportive evidence from epidemiological studies that it is transmissible (notably by blood transfusion 29, 30 ), we consider it important to evaluate the risks of iatrogenic transmission of CAA, and potentially of Alzheimer's disease. Given the lack of disease-modifying therapeutics for Alzheimer's disease and other distressing and fatal neurodegenerative conditions, it will be important to consider introducing improved methods for removing proteopathic seeds from surgical instruments on a precautionary basis.
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METHodS
Use of human tissues and research ethics. This study was carried out following ethics approval from the North East-Newcastle and North Tyneside 2 Research Ethics Committee (REC), reference 11/NE/0348, and the London Queen Square REC, reference 03/N038. The storage and biochemical analysis of human tissue samples and the transmission studies involving mice were performed in accordance with informed consent from all patients, from a person in a qualifying relationship to the deceased, or from a legal representative, in accordance with applicable UK legislation and regulatory codes of practice.
Anonymized post-mortem brain samples (three neuropathologically confirmed cases of Alzheimer's disease and one control with no signs of neurodegenerative disease) were provided under a material transfer agreement from the Queen Square Brain Bank for Neurological Disorders, UCL Institute of Neurology and Oxford Brain Bank, Oxford University Hospitals NHS Trust. Samples were obtained and used in accordance with the requirements of each providing tissue bank. Sourcing of archived c-hGH material. Human cadaveric pituitary-derived growth hormone material, from batches manufactured in the mid-1980s, is stored at Public Health England (PHE) under contract from the Department of Health and Social Care, with accompanying batch manufacturing records where available. Material from specific manufactured batches was supplied from this archive for the purposes of our study, on the request of the MRC Prion Unit at UCL and with the approval of the Department of Health and Social Care. All material has been stored at ambient temperature in sealed vials since the date of transfer to PHE. Biochemical analysis of c-hGH vials. The contents of each c-hGH vial were resuspended directly in 316 µl 6 M guanidine hydrochloride and all analyses were conducted with the investigator blinded to sample identity. For determination of Aβ x-40 concentrations, samples were diluted 12-fold before analysis on a Meso Scale Diagnostics platform, using anti-Aβ antibody 266 for capture and biotinylated 2G3 antibody for detection 31 . Aβ x-42 concentrations were determined following 72-fold dilution on an Erenna instrument (Quanterix, Lexington, MA, USA) using anti-Aβ antibody 266 for capture and fluorescently labelled 21F12 for detection 31 . Tau levels were determined by enzyme-linked immunosorbent assay (ELISA) following 144-fold dilution, with anti-tau antibody BT2 (Thermo Fisher Scientific) used for capture and alkaline-phosphatase-conjugated Tau5 antibody (Thermo Fisher Scientific) for detection 32 . We defined lower limits of quantification (LLoQs) for the determination of Aβ x-40 and tau levels as the lowest standards with a signal higher than the average signal for the blank plus 9 standard deviations (s.d.), allowing a percentage recovery of 100 ± 20% or more, and a coefficient of variance (CV) of 20% or less. The LLoQ for Aβ x-42 was defined as the lowest interpolated standard that provided a signal twofold that of the background with a percentage CV of 20% or less, and allows a percentage recovery of 100 ± 20% or more. Mouse transmission studies. Mouse studies were performed under approval and licence granted by the UK Home Office (Animals (Scientific Procedures) Act 1986), project licence number 70/9022, and conformed to UCL institutional and Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines (http:// www.nc3rs.org.uk/arrive-guidelines).
We used homozygous APP NL-F knock-in mice 20 that express APP bearing the Swedish (KM670/671NL) and Beyreuther/Iberian (I716F) mutations, and in which the Aβ domain has been humanized. These were speed-backcrossed (Jackson Laboratories, USA) and maintained on an inbred C57BL/6J background, and used as homozygotes (designated App
NL-F/NL-F
). Wild-type C57BL/6J mice were purchased from Jackson Laboratories via Charles River Laboratories. Mouse genotype was confirmed by polymerase chain reaction (PCR) of ear-punch DNA, and mice were uniquely identified by subcutaneous transponders. All of the mice used were female, as is our standard practice for long-term prion-transmission experiments, for reasons of consistency, animal welfare and logistics: increased fighting amongst groups of males requires them to be housed separately.
Mice (female, aged 6-8 weeks) were randomly assigned to experimental groups, anaesthetized with a mixture of halothane and O 2 , and intracerebrally inoculated into the right hemisphere in the parietal region with 30 µl of a 1% (w/v) human brain homogenate prepared in Dulbecco's PBS lacking Ca 2+ or Mg 2+ ions (D-PBS), vehicle (D-PBS) alone, 11 mg ml −1 rec-hGH (Humatrope Eli Lilly, UK), or c-hGH material prepared in D-PBS. For preparation of human brain homogenate, grey matter was dissected from frontal cortex samples of one healthy control brain and three Alzheimer's cases (AD 1-3) , homogenized using glass grinders with D-PBS at 10% (w/v), and subsequently diluted at 1% in D-PBS to inoculate the mice. Levels of Aβ 40 and Aβ 42 in the 10% homogenates were quantified using a V-Plex Aβ Peptide Panel 1 6E10 kit (Meso Scale Diagnostics platform), using anti-Aβ 40 and anti-Aβ 42 monoclonal antibodies for capture and anti-Aβ antibody 6E10 for detection. The healthy control brain had 2 ± 0.6 ng ml −1 Aβ 40 and 6.7 ± 2.8 ng ml −1 Aβ 42 . AD1 had 13.7 ± 0.6 ng ml −1 Aβ 40 and 30.5 ± 1.4 ng ml ± s.d.) . Note that the total Aβ peptide concentrations determined by biochemical assay may not relate to Aβ seeding activity. For transmission studies, each c-hGH vial was resuspended in 200 µl D-PBS and the contents of six vials from each batch were pooled before inoculation. This corresponds to each mouse receiving 0.75 IU of HWP51, 0.3 IU of HWP42 or 1 IU of rec-hGH. HWP42 was labelled as containing 2 IU per vial, whereas the HWP51 was labelled as containing 5 IU per vial; hence, although we used the same number of vials from each batch for inoculation, the dose of growth hormone was different. Calculated amounts of Aβ peptides in each 30-µl inoculum were as follows: HWP 42-Aβ x-40 , 43 pg; Aβ x-42 , below limit of quantitation; HWP 51-Aβ x-40 , 149 pg; Aβ x-42 , 20 pg. Inocula were prepared following strict biosafety protocols in a microbiological containment level III laboratory, and inoculations performed within a class 1 microbiological safety cabinet, using disposable equipment to prepare each inoculum. Safety cabinets were decontaminated before preparing inocula to avoid cross-contamination. Mice were culled at 8 months post-inoculation by exposure to CO 2 ; brains were then removed and prepared for immunohistochemistry. Antibodies and immunohistochemistry. Tissue was fixed in 10% buffered formal saline and incubated in 98% formic acid for 1 h. Following further washing in 10% buffered formal saline, tissue samples were processed and paraffin wax embedded. Serial sections of 5 µm nominal thickness were taken. Aβ deposition was visualized using biotinylated 82E1 (catalogue number 10326, IBL, Japan) as the primary antibody, using a Ventana Discovery automated immunohistochemical staining machine (Roche, Burgess Hill, UK) and proprietary solutions. Visualization was accomplished with development of 3′3-diaminobenzidine tetrahydrochloride as the chromogen (DAB Map Kit, Ventana Medical Systems). Haematoxylin was used as the counterstain. Image capture. Histological slides were digitized on a LEICA SCN400F scanner (LEICA Milton Keynes, UK) at ×40 magnification and 65% image-compression setting during export. Slides were archived and managed on LEICA Slidepath (LEICA Milton Keynes, UK). Quantification of CAA and parenchymal Aβ protein. All immunohistochemical quantification was performed blind to experimental group. CAA was present in small meningeal vessels and occasionally in small superficial cortical vessels. Because of the small size of meningeal vessels, reliable automated image analysis of CAA was not possible, and negative and positive vessels were quantified by visual inspection. One paramedian (approximately 200 µm) sagittal section per mouse was analysed. The extent of the CAA was determined by counting the number of Aβ-negative and -positive blood vessels in six anatomical areas of the meninges covering the dorsal part of the brain, including the olfactory bulb and the cerebellum.
Parenchymal Aβ, present in the form of diffuse deposits or as plaques, is amenable to image quantification on whole-slide images as described previously 1 . All Aβ-immunostained sagittal sections (approximately 200 µm parasagittal) of whole mouse brains were digitized as described above. Digital image analysis on whole slides was performed using Definiens Developer XD 2.6 (Definiens, Munich, Germany). Initial tissue identification was performed using a resolution equivalent to ×10 magnification, and stain detection was performed at ×20 magnification. Regions of interest (ROIs) were manually selected to separate the cortex, hippocampus and cerebellum; larger artefacts were also manually selected for exclusion from analysis. Tissue detection and initial segmentation was done to identify all tissue within the image, separating the sample from background and non-tissue regions for further analysis. This separation was based on identification of the highly homogeneous relatively bright/white region of background present at the perimeter of each image. A composite raster image produced by selecting the lowest pixel value from the three constituent colour layers (RGB colour model) provided a greyscale representation of brightness. The mean brightness of this background region was used to exclude all background regions from further analysis.
Stain detection (brown) was based on transformation of the RGB colour model to a hue-saturation-density (HSD) representation 33 . This provides a raster image of the intensity of each colour of interest (brown and blue). A number of fixed thresholds (T x ) was then used to identify areas of interest (A x ). The thresholds used were in arbitrary units (AU), with a scale of 0 AU to 3 AU in HSD images. The threshold T brown stain was allocated the value 0.15 AU, with all pixels above this threshold classed as 'stain' (A stain ) and those below as 'unstained' (A unstained ). A stain was excluded if the intensity of blue staining was not significantly lower than the intensity of brown stain (that is, if the difference was less than 0.1 AU), in order to remove generically dark areas. The remaining A stain areas were further categorized using a threshold T dark brown of 0.5 AU, to give A light and A dark .
Plaques were then constructed from these A light and A dark objects. Each A dark area was classified as a plaque seed; these were then grown into all surrounding A light areas to give A potential plaque (constructed of A light and A dark ) and A non-plaque (constructed of only A light ). Several exclusions were then applied, as follows. Any A potential plaque regions with an area less than 20 µm 2 (see below) or containing fewer than three pixels previously classified as A dark were reclassified as A non-plaque . The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Data analysis
Digital image analysis on whole slides was performed using Definiens Developer XD 2.6 (Definiens, Munich, Germany), as described in the Methods section. All statistical analysis and graphs were generated using the package GraphPad PRISM v6 (GraphPad Software, Inc., La Jolla, USA).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub All studies must disclose on these points even when the disclosure is negative.
Sample size
At the time the study commenced, there were no published studies involving inoculation of AD brain material into the AppNL-F/NL-F mice. Given the potential for loses due to intercurrent illness during a study lasting up to sixteen months, the choice of group size of 15 mice was informed by our experience of prion transmission experiments and literature studies of transmission of AD material using other mouse models. For subsequent experiments smaller group sizes of either ten (for c-hGH studies) or five mice (for short time points using AD brain material) were used. This was following power calculations and allowing for the likely lower titre and scarcity of the archived c-hGH material.
Data exclusions No data were excluded from the analysis.
Replication
Transmission studies used scarce and irreplaceable archived material and are very long duration studies involving animals; extensive control groups were included. We did not therefore repeat these studies.
Randomization Wild type mice were purchased from Charles River Laboratories and randomly assigned to experimental groups. AppNL-F/NL-F mice were bred in-house with groups being populated with mice as soon as they became available. Staff was blind to experimental groups.
Blinding
All biochemical analyses and immunohistochemical quantification were conducted with the investigator blind to sample identity.
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